SCHEMBL2186774

SCHEMBL2186774

Cn1cnc(-c2nc(N)c3nccnc3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.42
LRRK2 Q5S007 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2E1 P05181 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2B6 P20813 1/20 0.36
KDM2B Q8NHM5 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM5A P29375 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
CDK1 P06493 1/20 0.30
MAPT P10636 1/20 0.30
TSHR P16473 1/20 0.30
MTOR P42345 1/20 0.30
HRH4 Q9H3N8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190316 0.78 ADORA1 (0.53) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL2185605 0.69 ADORA2A (0.46) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL2188560 0.69 ADORA1 (0.58) ADORA2AADORA1ADORA3HRH4
SCHEMBL2190600 0.68 CYP2C9 (0.42) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL16547507 0.67 CYP2C9 (0.52) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL2184224 0.67 ADORA2A (0.47) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL2187983 0.67 ADORA2A (0.56) ADORA2AADORA1LRRK2CYP2C9CYP2C19
SCHEMBL28637477 0.66 ADORA2A (0.53) ADORA2AADORA1ADORA3MAPT
SCHEMBL22055303 0.65 ADORA2A (0.63) ADORA2AADORA1ADORA3
SCHEMBL2187562 0.65 LRRK2 (0.42) ADORA2AADORA1LRRK2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346859-A1 HETEROCYCLIC JAK KINASE INHIBITORS AstraZeneca AB (SE) 2011-07-27 EP disclosed